icosiMED

The global rise in obesity has created a huge need for lasting weight management solutions. While GLP-1 drugs work short-term, 80% of patients stop treatment and regain weight. icosiMED is developing a first-in-class oral therapy that drives fat loss without muscle loss or appetite suppression by mimicking the benefits of fasting without dieting. With 74% of U.S. adults overweight or obese, icosiMED is poised to deliver a valuable preclinical asset in the multi-billion-dollar weight management market.